Chemokines and other mediators as therapeutic targets in psoriasis vulgaris

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 539-545

  Homey, Bernhard ^a   Meller, Stephan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABX IL8; CHEMOATTRACTANT; CUTANEOUS T CELL ATTRACTING CHEMOKINE; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 22; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ACANTHOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; T LYMPHOCYTE ACTIVATION;

CELL COMMUNICATION; CHEMOKINES; CYTOKINES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PSORIASIS;

EID: 49849092644     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.11.003     Document Type: Article

References (77)

1. Elder J.T., Nair R.P., and Voorhees J.J. Epidemiology and the genetics of psoriasis. J Invest Dermatol 102 (1994) 24S-27S
2. Ortonne J.P. Aetiology and pathogenesis of psoriasis. Br J Dermatol 135 Suppl 49 (1996) 1-5
3. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., and Cooper K.D. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 105 (1995) 89S-94S
4. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
5. Butcher E.C., and Picker L.J. Lymphocyte homing and homeostasis. Science 272 (1996) 60-66
6. Zlotnik A., Morales J., and Hedrick J.A. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 19 (1999) 1-47
7. Rossi D., and Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 18 (2000) 217-242
8. Luttichau R., Stine J., Boesen T.P., et al. A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J Exp Med 191 (2000) 171-180
9. Luttichau H.R., Gerstoft J., and Schwartz T.W. MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human but not murine CCR8. J Leukoc Biol 70 (2001) 277-282
10. Plant D., Young H.S., Watson R.E., Worthington J., and Griffiths C.E. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol 15 (2006) 900-903
11. DeVries M.E., Cao H., Wang J., et al. Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus. J Biol Chem 278 (2003) 11985-11994
12. Raychaudhuri S.P., Jiang W.Y., and Farber E.M. Cellular localization of fractalkine at sites of inflammation: antigen-presenting cells in psoriasis express high levels of fractalkine. Br J Dermatol 144 (2001) 1105-1113
13. Giustizieri M.L., Mascia F., Frezzolini A., et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107 (2001) 871-877
14. Morita E., Kameyoshi Y., Hiragun T., Mihara S., and Yamamoto S. The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 56 (2001) 194-195
15. Raychaudhuri S.P., Jiang W.Y., Farber E.M., Schall T.J., Ruff M.R., and Pert C.B. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79 (1999) 9-11
16. Rottman J.B., Smith T.L., Ganley K.G., Kikuchi T., and Krueger J.G. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 81 (2001) 335-347
17. Uchida T., Suto H., Ra C., Ogawa H., Kobata T., and Okumura K. Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. Int Immunol 14 (2002) 1431-1438
18. Homey B., Dieu-Nosjean M.C., Wiesenborn A., et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164 (2000) 6621-6632
19. Homey B., Alenius H., Muller A., et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 8 (2002) 157-165
20. Kakinuma T., Saeki H., Tsunemi Y., et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 111 (2003) 592-597
21. Gillitzer R., Ritter U., Spandau U., Goebeler M., and Brocker E.B. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 107 (1996) 778-782
22. Schröder J.M., and Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 87 (1986) 53-58
23. Flier J., Boorsma D.M., van Beek P.J., et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194 (2001) 398-405
24. Yamashita T., Akamatsu H., Tomitaka A., Ogawa Y., Sugawara N., and Matsunaga K. IP-10 in atopic dermatitis. Allergy 58 (2003) 261
25. Fraticelli P., Sironi M., Bianchi G., et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107 (2001) 1173-1181
26. Ong P.Y., and Leung D.Y. The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and is decreased in atopic dermatitis as compared with psoriasis. J Invest Dermatol 119 (2002) 1463-1464
27. Kulke R., Bornscheuer E., Schluter C., et al. The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110 (1998) 90-94
28. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
29. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256 (1986) 3110-3116
30. + T cells induces psoriasis. Am J Pathol 155 (1999) 145-158
31. + T cells. Nat Med 3 (1997) 183-188
32. Schon M.P. Animal models of psoriasis-what can we learn from them?. J Invest Dermatol 112 (1999) 405-410
33. Wrone-Smith T., and Nickoloff B.J. Dermal injection of immunocytes induces psoriasis [see comments]. J Clin Invest 98 (1996) 1878-1887
34. Bos J.D., Van Leent E.J., and Sillevis Smitt J.H. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol 7 (1998) 132-138
35. Ruzicka T., Bieber T., Schopf E., et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 337 (1997) 816-821
36. Leung D.Y., and Bieber T. Atopic dermatitis. Lancet 361 (2003) 151-160
37. Meller S., Winterberg F., Gilliet M., et al. UV injury, chemokines and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52 (2005) 1504-1516
38. Picker L.J., Treer J.R., Ferguson-Darnell B., Collins P.A., Bergstresser P.R., and Terstappen L.W. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol 150 (1993) 1122-1136
39. Picker L.J., Terstappen L.W., Rott L.S., Streeter P.R., Stein H., and Butcher E.C. Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol 145 (1990) 3247-3255
40. Picker L.J., Martin R.J., Trumble A., et al. Differential expression of lymphocyte homing receptors by human memory/effector T cells in pulmonary versus cutaneous immune effector sites. Eur J Immunol 24 (1994) 1269-1277
41. Picker L.J. Regulation of tissue-selective T-lymphocyte homing receptors during the virgin to memory/effector cell transition in human secondary lymphoid tissues. Am Rev Respir Dis 148 (1993) S47-S54
42. Santamaria L.F., Perez Soler M.T., Hauser C., and Blaser K. Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitis and atopic dermatitis are associated with the cutaneous lymphocyte antigen. Int Arch Allergy Immunol 107 (1995) 359-362
43. Santamaria Babi L.F., Picker L.J., Perez Soler M.T., et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med 181 (1995) 1935-1940
44. Santamaria Babi L.F., Moser R., Perez Soler M.T., Picker L.J., Blaser K., and Hauser C. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1). J Immunol 154 (1995) 1543-1550
45. Berg E.L., Yoshino T., Rott L.S., et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med 174 (1991) 1461-1466
46. Catalina M.D., Estess P., and Siegelman M.H. Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E- and P- but not L-selectin. Blood 93 (1999) 580-589
47. Groves R.W., Allen M.H., Barker J.N., Haskard D.O., and MacDonald D.M. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 124 (1991) 117-123
48. Homey B., Wang W., Soto H., et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 164 (2000) 3465-3470
49. Morales J., Homey B., Vicari A.P., et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci U S A 96 (1999) 14470-14475
50. Gottlieb A.B., Masud S., Ramamurthi R., et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48 (2003) 68-75
51. Kinney T., Rawlins M., Kozarek R., France R., and Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98 (2003) 608-612
52. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61 (2002) ii70-ii73
53. Reiss Y., Proudfoot A.E., Power C.A., Campbell J.J., and Butcher E.C. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 194 (2001) 1541-1547
54. Campbell J.J., Haraldsen G., Pan J., et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400 (1999) 776-780
55. Wells T.N., Power C.A., Shaw J.P., and Proudfoot A.E. Chemokine blockers-therapeutics in the making?. Trends Pharmacol Sci 27 (2006) 41-47
56. Dieu M.C., Vanbervliet B., Vicari A., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188 (1998) 373-386
57. Dieu-Nosjean M.C., Massacrier C., Homey B., et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 192 (2000) 705-718
58. Liao F., Rabin R.L., Smith C.S., Sharma G., Nutman T.B., and Farber J.M. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 162 (1999) 186-194
59. Diepgen T.L. Atopic dermatitis: the role of environmental and social factors, the European experience. J Am Acad Dermatol 45 (2001) S44-S48
60. Kauffman C.L., Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123 (2004) 1037-1044
61. Trinchieri G., Pflanz S., and Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19 (2003) 641-644
62. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
63. Park H., Li Z., Yang X.O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (2005) 1133-1141
64. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
65. Rahman M.S., Yamasaki A., Yang J., Shan L., Halayko A.J., and Gounni A.S. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2 JNK, and p38) pathways. J Immunol 177 (2006) 4064-4071
66. Kao C.Y., Huang F., Chen Y., et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol 175 (2005) 6676-6685
67. Ruddy M.J., Shen F., Smith J.B., Sharma A., and Gaffen S.L. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukoc Biol 76 (2004) 135-144
68. Katz Y., Nadiv O., and Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. Arthritis Rheum 44 (2001) 2176-2184
69. Takaya H., Andoh A., Makino J., et al. Interleukin-17 stimulates chemokine (interleukin-8 and monocyte chemoattractant protein-1) secretion in human pancreatic periacinar myofibroblasts. Scand J Gastroenterol 37 (2002) 239-245
70. Witowski J., Pawlaczyk K., Breborowicz A., et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 165 (2000) 5814-5821
71. Toichi E., Torres G., McCormick T.S., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 177 (2006) 4917-4926
72. Chan J.R., Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203 (2006) 2577-2587
73. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22 (2004) 929-979
74. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., and Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174 (2005) 3695-3702
75. Gurney A.L. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 4 (2004) 669-677
76. Sa S.M., Valdez P.A., Wu J., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178 (2007) 2229-2240
77. Wolk K., Witte E., Wallace E., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36 (2006) 1309-1323